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A B S T R A C T
The primary goals of long-term disease management in non-cystic fibrosis bronchiectasis (NCFB) are to reduce
the number of exacerbations, and improve quality of life. However, currently no therapies are licensed for this.
Ciprofloxacin Dry Powder for Inhalation (Ciprofloxacin DPI) has potential to be the first long-term intermittent
therapy approved to reduce exacerbations in NCFB patients.
The RESPIRE programme consists of two international phase III prospective, parallel-group, randomized,
double-blinded, multicentre, placebo-controlled trials of the same design. Adult patients with idiopathic or post-
infectious NCFB, a history of ≥2 exacerbations in the previous 12 months, and positive sputum culture for one
of seven pre-specified pathogens, undergo stratified randomization 2:1 to receive twice-daily Ciprofloxacin DPI
32.5 mg or placebo using a pocket-sized inhaler in one of two regimens: 28 days on/off treatment or 14 days on/
off treatment. The treatment period is 48 weeks plus an 8-week follow-up after the last dose. The primary
efficacy endpoints are time to first exacerbation after treatment initiation and frequency of exacerbations using a
stringent definition of exacerbation. Secondary endpoints, including frequency of events using different
exacerbation definitions, microbiology, quality of life and lung function will also be evaluated.
The RESPIRE trials will determine the efficacy and safety of Ciprofloxacin DPI. The strict entry criteria and
stratified randomization, the inclusion of two treatment regimens and a stringent definition of exacerbation
should clarify the patient population best positioned to benefit from long-term inhaled antibiotic therapy.
Additionally RESPIRE will increase understanding of NCFB treatment and could lead to an important new
therapy for sufferers.
Trial registration: The RESPIRE trials are registered in ClinicalTrials.gov, ID number NCT01764841
(RESPIRE 1; date of registration January 8, 2013) and NCT02106832 (RESPIRE 2; date of registration April
4, 2014).
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1. Background
Non-cystic fibrosis bronchiectasis (NCFB) is a chronic respiratory
disease, characterized by abnormal dilation of the bronchi leading to a
cycle of inflammation and infection and reduced quality of life [1–5].
NCFB is associated with significant morbidity, and mortality of up
to twofold higher than in the general population [6–8]. Frequent
exacerbations are associated with a lower quality of life [9], future
exacerbations, increased morbidity and mortality [10,11], and are
likely linked to disease progression [12]. Mean exacerbation rates of
1.0 to 2.6 per year have been reported [10,13–15] and nearly 50% of
patients, in at least one series, experience two or more exacerbations
per year [16].
Reducing the number and frequency of exacerbations is a primary
aim of long-term disease management [1]. There are currently no
licensed therapies to reduce acute exacerbations and treatment ap-
proaches are primarily derived from studies in cystic fibrosis (CF).
Inhaled antibiotic trials in NCFB have had largely disappointing results;
some therapies have not demonstrated significant impacts on exacer-
bation rate [13,17–19] while others have reported unanticipated
pulmonary adverse events [20–22]. To date, only a small, open-label,
randomized study of continuous nebulized gentamicin achieved its
primary endpoint [23]. Long-term therapy with oral macrolides has
also been shown to reduce exacerbations [24–26]; however, studies
have differed in design and patient population. Consequently the
appropriate target patient population, drug, dose and risk-benefit of
long-term use remain unclear [27].
Despite the critical impact of exacerbations on patients, there is
neither a current validated or universally accepted definition for
exacerbation nor established criteria for assessing the severity of
exacerbations. Identifying and documenting an exacerbation in patients
with chronic presence of bacterial pathogens in sputum culture and
fluctuating symptoms can also be challenging, particularly as many
patients start rescue antibiotics promptly in response to symptoms
potentially suggestive of the onset of an exacerbation. The definition of
exacerbation varies between clinical studies and sometimes includes
symptoms caused by respiratory viruses or other events antibacterial
therapy is not appropriate. The RESPIRE studies use two definitions of
exacerbation: a stringent definition, in order to reduce the impact of
variability in clinical assessments on efficacy outcomes; and a compara-
tively ‘less stringent’ definition which will act as a confirmatory
analysis and provide insight into the impact of exacerbation definition
on clinical endpoints.
Ciprofloxacin Dry Powder for Inhalation (Ciprofloxacin DPI) is an
inhaled antibiotic consisting of capsules containing 32.5 mg ciproflox-
acin inhalation powder which is formulated using Novartis'
PulmoSphere™ technology. The drug is delivered by a pocket-sized
inhaler (Fig. 1). Each capsule contains 32.5 mg ciprofloxacin inhalation
powder. Patients administer Ciprofloxacin DPI twice daily; the dose can
be delivered in one-to-two breaths. Dry powder inhalers have a short
administration time, improved portability and require no intensive
cleaning [28]; features that could potentially promote treatment
adherence.
Ciprofloxacin DPI was developed to delay and reduce exacerbations
and improve quality of life in NCFB patients with frequent exacerba-
tions and evidence of respiratory pathogens. A phase II, randomized,
double-blind, placebo-controlled study of Ciprofloxacin DPI 32.5 mg for
28 days in patients with NCFB was promising, with significant reduc-
tions in total sputum bacterial load at end-of-treatment and a favour-
able safety and tolerability profile [29].
Ciprofloxacin DPI aims to be the first long-term intermittent therapy
approved in NCFB. This paper describes the unique study design of
phase III RESPIRE programme for Ciprofloxacin DPI in NCFB, the
largest trial programme yet conducted in this population.
2. Methods/design
2.1. Aims
The primary objectives of the RESPIRE studies are to evaluate the
efficacy of Ciprofloxacin DPI in prolonging the time to first exacerba-
tion and reducing the frequency of exacerbations with two treatment
regimens (28 days on/off and 14 days on/off) in patients with NCFB
using a stringent definition of exacerbation.
Secondary objectives of these studies are to evaluate microbiology,
quality of life, and lung function, in patients with NCFB treated with
Ciprofloxacin DPI or placebo.
2.2. Exacerbation definitions
The two primary endpoints of time to first and frequency of
exacerbations use a stringent definition of exacerbation. For stringently
defined events occurring during the study, three criteria are required to
be met:
1) Worsening of at least three signs or symptoms (dyspnoea,
wheezing, cough, 24-hour sputum volume or sputum purulence) for
at least 2 consecutive days (beyond normal day-to-day variations)
2) Fever (body temperature > 38.0 °C) OR malaise/fatigue
3) Treatment with systemic antibiotic(s).
This stringent definition of exacerbation will also be used for the
first secondary endpoints.
A comparatively less stringent definition of exacerbation will be
used for second secondary endpoints (Table 1). For this definition only
two criteria are required to be met:
1) Worsening of one or more signs or symptoms (dyspnoea, wheezing,
cough, 24-hour sputum volume or sputum purulence)
2) Treatment with systemic antibiotic(s).
Fig. 1. Ciprofloxacin DPI consisting of capsules containing ciprofloxacin inhalation powder and a pocket-sized inhale.
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2.3. Study design
The RESPIRE programme consists of two trials (RESPIRE 1 and
RESPIRE 2) that are of the same design but which differ slightly in their
analysis plans. Both trials are prospective, parallel-group, randomized,
double-blinded, multicentre, placebo-controlled trials in which patients
with NCFB are randomized 2:1 to receive long-term intermittent
regimens of twice-daily Ciprofloxacin DPI 32.5 mg or matching place-
bo. Outpatient clinics in Australia/New Zealand, Asia, Europe, Middle
East, South Africa, and North and South America are participating.
The two intermittent Ciprofloxacin DPI regimens being studied in
both RESPIRE 1 and RESPIRE 2 are: cycles of 14 days on- and 14 days
off-drug or 28 days on- and 28 days off-drug (Fig. 2). Each active
treatment group has a parallel placebo arm.
The treatment period in the RESPIRE trials is 48 weeks, followed by
8 weeks of off-treatment follow-up after the last study drug dose. The
screening visit (Visit 1) is conducted from days 0 to 28 prior to the first
study drug administration at randomization (Visit 2). Throughout the
study, clinical, bacteriological and laboratory examinations will be
performed. For pathogens, the bacterial species cultured at screening
and on randomization are combined to form the baseline. For all other
measurements, the last non-missing data point before the start of
treatment is considered baseline. Following the randomization visit,
study visits or calls are conducted at regular intervals during the 48-
week treatment period, depending on the treatment regimen. Each visit
includes collection of a sputum sample (before inhalation of the study
drug); assessment of vital signs, and respiratory signs and symptoms;
pulmonary function tests; a physical examination; and review of
concomitant therapy, adverse events and hospitalizations for exacerba-
tions. The St George's Respiratory Questionnaire (SGRQ) is completed
at randomization, at end of on-treatment cycle 6 (14 day regimen) and
cycle 3 (28 day regimen), end of treatment (EOT) and end of study
(EOS). Quality of Life-Bronchiectasis (QoL-B) questionnaire data is
collected a total of nine (28 day regimen) or ten (14 day regimen) times
throughout the study, including time points at EOT and EOS. Nasal
swabs, blood and sputum samples for inflammatory markers and
samples for pharmacokinetic analyses are collected at baseline and
periodically thereafter. Telephone calls from the study site are used to
remind the patient of the start of a new treatment cycle; check
treatment compliance and results of home pregnancy tests; as well as
to review adverse events, hospitalizations and changes in concomitant
therapy. The EOT visit takes place at the end of the on-treatment phase
in the last treatment cycle. EOT assessments are also performed for
patients who discontinued the study prematurely. The EOS visit occurs
8 weeks after the last dose for both the 14 days on/off and 28 days on/
off regimen.
Documented approval from Independent Ethics Committees and
Institutional Review Boards was obtained from all participating cen-
tres/countries before the start of the study, according to Good Clinical
Practice and local laws and regulations. Written informed consent was
obtained from all participants.
2.4. Intervention
Ciprofloxacin DPI and matched placebo are provided as capsules for
inhalation. The dose is delivered by a pocket-sized, portable, breath-
actuated, dry powder inhaler (T-326) supplied by Novartis, San Carlos,
CA (Fig. 1). The contents of a capsule, containing 35.5 mg of cipro-
Table 1
Efficacy and safety endpoints for RESPIRE.
Primary efficacy
FDA EMA/others
• Time to first exacerbation using a stringent exacerbation definition (comparison
vs pooled placebo)
• Frequency of exacerbation events using a stringent exacerbation definition (comparison
vs matched placebo)
Secondary efficacy (comparison vs pooled placebo unless otherwise stated)
• Frequency of exacerbation events using a stringent exacerbation definition• Frequency of exacerbation events with less stringent exacerbation definition• Pathogen eradication• QoL measured by SGRQ symptoms component score• Occurrence of new pathogens not present at baseline• QoL measured by QOL-B Respiratory symptom domain• Improving lung function measured by FEV1
• Time to first exacerbation event using a stringent exacerbation definition• Frequency of exacerbation events with less stringent definition of exacerbation (vs
matched placebo)
• Pathogen eradication• QoL measured by SGRQ symptoms component score• Occurrence of new pathogens not present at baseline• QoL measured by QOL-B Respiratory symptom domain• Improving lung function measured by FEV1
Additional efficacy variables
• Frequency/time to exacerbation using a stringent exacerbation definition and:
○ with fever (> 38 °C).
○ requiring hospitalization.
○ associated with the presence of P. aeruginosa.
○ verified by a 10% drop in FEV1 compared to the last pre-exacerbation measurement.
• Frequency/time to exacerbation of all investigator reported exacerbations (including those not fulfilling stringent or less stringent definition).• Changes from baseline in FVC and FEV1/FVC (post-bronchodilator spirometry).• Changes from baseline in inflammatory markers (high-sensitivity C-reactive protein, polymorphonuclear leukocytes).• Shift in MIC over time.• Changes from baseline in sputum inflammatory markers interleukin-8 and myeloperoxidase.
Safety variables
• Occurrence of any adverse events, including deaths and other serious adverse events.• Occurrence of inhalation-induced bronchospasm on the day of the first administration (defined as pre–post drop in FEV1 of ≥15% from baseline).• Changes in safety laboratory values.• Development of ciprofloxacin-resistant pathogenic bacterial isolates.• Presence of NTM.• Presence of recurring or new pathogens.
EOT, end of therapy; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; MIC, minimum inhibitory concentration; NTM, non-tuberculous mycobacteria; QOL-B, Quality of
Life-Bronchiectasis; SGRQ, St George's Respiratory Questionnaire.
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floxacin or placebo, are inhaled in one breath, or two breaths if needed,
twice daily. On every treatment day, study drug administration by
inhalation is performed once in the morning and once in the evening
after completion of the patient's regular bronchiectasis treatment.
2.5. Entry criteria
Inclusion and exclusion criteria for the RESPIRE trials are shown in
Table 2. Briefly, the studies include adult patients with a confirmed
diagnosis of post-infectious or idiopathic NCFB based on a computed
tomography scan including two or more lobes. Patients are required to
have forced expiratory volume in 1 s (FEV1) between ≥30% and<
90% predicted, a history of ≥2 documented exacerbations in the past
12 months, and a positive sputum culture at screening visit for
Pseudomonas aeruginosa or one of six other pre-specified pathogens
(Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influen-
zae, Moraxella catarrhalis, Stenotrophomonas maltophilia, Burkholderia
cepacia) as confirmed by a central microbiology laboratory. It is
important to note that the two exacerbations reported in the prior year
are not required to meet the stringent definition of exacerbation used
for the primary endpoints of the study. Patients with certain underlying
diseases, including cystic fibrosis, potentially associated with bronch-
iectasis are excluded from the RESPIRE studies (Table 2).
2.6. Randomization and masking
Randomization and medication kit numbers are generated by
Bayer's Randomization Management. Drug dispensation is managed
by an interactive voice response system and interactive web response
system run by an external vendor. At the randomization visit (Visit 2),
patients receive a unique randomization number that allows subsequent
identification of their randomized treatment group allocation. Patients
in the study are randomized 2:1 (Ciprofloxacin DPI:placebo) and
stratified for randomization based on chronic macrolide use, positive
P. aeruginosa sputum culture and geographic region.
The study is blinded for treatment assignment, but not for treatment
regimen (i.e., 28 days on/off treatment regimen or 14 days on/off
regimen), as the length of treatment cycles must be known to patients
Fig. 2. Treatment schedule of the RESPIRE trials.
DPI, dry powder for inhalation. Treatment administered twice daily.
Table 2
Key patient entry criteria for RESPIRE.
Main inclusion criteria Main exclusion criteria
• Age≥ 18 years.• Proven and documented diagnosis of idiopathic or post-infectious NCFB by computed
tomography scan, including two or more lobes and dilated airways compatible with
bronchiectasis at initial diagnosis.
• Positive culture from an adequate sputum sample at screening for:
○ Pseudomonas aeruginosa
○ Haemophilus influenzae
○ Moraxella catarrhalis
○ Staphylococcus aureus
○ Streptococcus pneumoniae
○ Stenotrophomonas maltophilia
○ Burkholderia cepacia.
• History of ≥2 documented exacerbations in the past 12 months.• Stable pulmonary status as indicated by FEV1≥ 30% and< 90% predicted.• Stable regimen of standard treatment with:
○ bronchodilators, anticholinergics, inhaled corticosteroids or mucolytics, if used as
chronic treatment for bronchiectasis, at least for the past 4 weeks prior to screening.
Patients on maintenance therapy with low-dose systemic corticosteroids should be
receiving ≤10 mg/day prednisolone equivalent at least for the past 4 weeks before
the screening visit.
○ macrolides if used as chronic treatment for bronchiectasis for at least 6 months prior
to screening.
• Sputum production on the majority of days.
• FEV1 < 30% or ≥90% predicted (post-bronchodilator).• Active allergic bronchopulmonary aspergillosis.• Active and actively treated non-tuberculous mycobacterial infection or
tuberculosis.
• Recent significant haemoptysis (≥300 mL or requiring blood transfusion) in
the preceding 4 weeks before screening (and during the screening period).
• Primary diagnosis of COPD.• Known CF and/or documented chronic bronchial asthma.• Medical history of allergies to quinolones or fluoroquinolones.
CF, cystic fibrosis; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; NCFB, non-cystic fibrosis bronchiectasis.
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and investigators. When knowledge of the study drug is essential for the
clinical management or welfare of the patient, the investigator may
unblind a patient's treatment assignment.
2.7. Endpoints
2.7.1. Primary endpoints
Two different analysis plans have been agreed with two different
regulatory organisations, i.e. the United States Food and Drug
Administration (‘FDA’) and the European Medicines Agency and other
ex-US agencies (‘EMA/others’) (Table 1). The primary endpoints agreed
with authorities are:
1) Time to first exacerbation within 48 weeks after start of treatment
(FDA)
2) Frequency of exacerbations during the 48-week study (EMA/
others).
Time to first exacerbation (time from randomization until the visit
at which the first qualifying exacerbation was recorded) will be
evaluated against a pooled placebo group, and the frequency of
exacerbations will be evaluated against matched placebo groups (i.e.
Ciprofloxacin DPI 14 days on/off is compared to placebo 14 days on/off
and Ciprofloxacin DPI 28 days on/off is compared to placebo 28 days
on/off).
2.7.1.1. Exacerbations. Patients who experience worsening of
respiratory signs and symptoms are required to attend an
unscheduled visit with the investigator during which they provide a
fresh sputum sample and undergo a physical examination to evaluate
the signs and symptoms of exacerbations. Confirmed exacerbations are
reported in the validated electronic system. For the primary endpoints,
and first secondary endpoints, a stringent definition of exacerbation
will be used (Table 1); exacerbations must fulfil all criteria to be
deemed a qualifying event.
Study treatment may be temporarily interrupted during an acute
exacerbation for the time of systemic antibiotic treatment. Thereafter,
treatment with Ciprofloxacin DPI is to be continued according to the
original treatment schedule.
2.7.2. Secondary endpoints
Table 1 presents a complete list of pre-specified secondary efficacy
endpoints. Secondary endpoints will be evaluated by hierarchical
testing in the order shown in Table 1 (e.g., once an endpoint does not
meet the test for significance, all subsequent tests are no longer
evaluated for statistically significant endpoint results, although they
will be assessed for exploratory purposes).
Secondary endpoints involve further aspects that are important to
the long-term management of NCFB patients. Microbial analyses
(microbial re-identification and susceptibility testing) are performed
by a central laboratory. Frequency of exacerbation events using a less
stringent definition of exacerbation will be used as a confirmatory
analysis and to provide insight into the impact of exacerbation
definition on clinical endpoints.
2.7.3. Additional endpoints
Changes in spirometry values (FVC and FEV1/FVC) and inflamma-
tory markers are being assessed as additional endpoints. A number of
alternative definitions of exacerbation, addressing individual compo-
nents of exacerbation definition such as fever and hospitalization, will
also be evaluated for time to exacerbation and frequency of exacerba-
tion assessments (Table 1).
2.7.4. Safety endpoints
Safety analyses include the occurrence of adverse events, the
occurrence of inhalation-induced bronchospasm (decrease in
FEV1≥ 15% [absolute value] following study drug administration),
and changes in laboratory safety values. The presence of non-tubercu-
lous mycobacteria (NTM) or Aspergillus as well as the presence of new
or recurring pathogens and development of ciprofloxacin-resistant
pathogenic bacterial isolates will also be analysed. Adverse events of
special interest include bronchospasm, hemoptysis, hypersensitivity
reaction and tendon disorder. RESPIRE 1 includes a safety analysis,
performed by an independent Data Safety Monitoring Committee after
at least 100 patients have completed day 168 of the clinical study. The
safety assessment will evaluate all available data to that date in order to
determine patient safety and to decide on continuation of the study.
2.8. Statistical analysis
2.8.1. Sample size
Sample size calculations are based on the primary efficacy variable
of time to first protocol-defined exacerbation, using the stringent
definition (Table 1). Assuming that Ciprofloxacin DPI prolongs median
time to first exacerbation by 67%, a total of 200 first exacerbation
events across all treatment arms are needed to show a prolongation in
time to first exacerbation for at least one active regimen over pooled
placebo with a study-wise power of 90% and a study-wise α of 0.05.
The required sample size has been determined based on blinded
data, taking into account observed and expected exacerbation data. The
expected proportion of patients with an event before EOT is estimated
as well as the exponential drop-out rate and expected proportion of
drop-outs. In addition, the expected proportion of patients prematurely
discontinuing before an event is estimated. Recruitment is terminated
when it could be expected that the required number of qualifying
exacerbations, as defined within the study protocol, would be reached
with the enrolled patients within the planned treatment period.
For the corresponding analysis of frequency of exacerbations within
48 weeks, the same assumptions as above are used; based on the sample
size determined, the comparison of the single active arm versus
matching placebo will have a power of at least 90%.
2.8.2. Efficacy analyses
Efficacy variables will be evaluated in the full analysis set (FAS),
defined as all randomized patients; the FAS is identical to the intent-to-
treat population. Analyses in the per protocol population (all patients in
the FAS with a compliance of ≥80% of planned capsules, and no
protocol violations influencing treatment efficacy) will serve as sup-
porting evidence. Both 14 day and 28 day regimens will be tested in
parallel. Primary variables will be tested first, followed by secondary
variables in hierarchical order as shown in Table 1. To protect the
study-wise α-level of 0.05, the alpha level, which is two-sided, will be
split between the tests for the two regimens. An individual study will be
considered successful if the hypothesis for the primary endpoint can be
rejected for at least one Ciprofloxacin DPI treatment regimen. As
highlighted above, two different analysis plans were agreed with the
regulatory authorities.
2.8.3. Primary endpoints
For the FDA primary endpoint of time to first exacerbation using a
stringent definition of exacerbation, a Cox proportional hazards model
will be used to test for differences between the Ciprofloxacin DPI groups
and pooled placebo group. The independent variables will be treatment
group, geographic region, baseline positive culture for P. aeruginosa and
chronic macrolide use. A logrank test will also be performed as a
sensitivity analysis.
For the EMA/others primary endpoint of frequency of exacerbations
using a stringent definition of exacerbation, a Poisson regression with
adjustment for over-/under-dispersion will be used to analyze the
frequency of exacerbations over 48 weeks. The model will include
treatment group, pre-therapy positive culture for P. aeruginosa, chronic
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macrolide use, geographic region as covariates and time in study as
offset. This endpoint will be tested against matched placebo.
2.8.4. Secondary endpoints
For the first secondary FDA endpoint of frequency of exacerbation
events (using the stringent definition of exacerbation) the Ciprofloxacin
DPI groups will be compared to pooled placebo using a Poisson
regression. In RESPIRE 1, time in study will not be included in the
model but rather the frequency of exacerbation events for patients who
discontinued will be extrapolated. The extrapolation rate agreed with
the regulatory authority is based on whether the patient had an
exacerbation event while on study drug (in patients without an
exacerbation event at time of withdrawal, the average event rate per
day of all treatment groups is used; in patients with at least one
exacerbation, the observed rate is linearly extrapolated to 48 weeks). In
RESPIRE 2 on the other hand, time in study will be used as an offset.
For the EMA/others first secondary endpoint of time to first
exacerbation (using the stringent definition of exacerbation) a Cox
proportional hazards model will be used to test for differences between
the Ciprofloxacin DPI groups and pooled placebo group. The indepen-
dent variables will be treatment group, geographic region, baseline
positive culture for P. aeruginosa and chronic macrolide use.
For both FDA and EMA/others second secondary endpoints of
frequency of exacerbation events using the less stringent definition of
exacerbation, a Poisson regression with adjustment for over-/under-
dispersion will be used as described previously with the FDA analysis
comparing to pooled placebo, and EMA/others analysis comparing to
matched placebo. Treatment group, positive baseline culture for P.
aeruginosa and geographic region and chronic macrolide use will be
used as covariates. In the EMA/others analysis plan for RESPIRE 1 and
2, and in the FDA analysis plan for RESPIRE 2, time in study will be
used as an offset. For the RESPIRE 1 FDA analysis of this endpoint, the
frequency of exacerbation events for patients who discontinued will be
extrapolated as for the primary endpoint.
Pathogen eradication (defined as a negative culture result at EOT for
the pre-specified baseline pathogen(s)) and acquisition of new patho-
gens (defined as presence of any of the pre-specified organisms not
cultured at baseline at EOT) will be analysed by a
Cochran–Mantel–Haenszel test. This will be stratified by geographic
region, pre-therapy positive culture for P. aeruginosa and chronic
macrolide use and will compare each Ciprofloxacin DPI arm against
pooled placebo.
Change from baseline to EOT in SGRQ symptoms component score,
QoL-B respiratory symptoms domain and FEV1 will be analysed for
Ciprofloxacin DPI versus pooled placebo using an analysis of covariance
model (ANCOVA) with baseline score as covariate and the following
factors: treatment group, baseline positive culture for P. aeruginosa,
chronic macrolide use and geographic region. Additional sensitivity
analyses with mixed-effect repeated measure models will also be
performed.
Planned subgroup analyses will provide descriptive statistics and
exploratory P values for patients with vs without positive baseline
culture of P. aeruginosa; FEV1 < 50% of predicted at baseline;
hospitalization due to exacerbation or> 2 exacerbations requiring
systemic antibiotic treatment in the previous year; persistent pathogen
culture (at least one organism in common at screening and randomiza-
tion visit) before start of study treatment; chronic macrolide use; and
ciprofloxacin resistant pathogen at baseline using Clinical Laboratory
Standards Institute breakpoints for systemic treatment with ciproflox-
acin.
2.8.5. Additional and safety endpoints
All other efficacy variables will be analysed descriptively using
summary statistics or frequency tables as appropriate, no interaction
model will be used.
Safety analyses will be performed in the safety population (which
includes all randomized patients who received study medication).
Adverse events will be considered treatment-emergent if they first
occurred at or after the first administration of study medication or
worsened during the course of the study up to and including 30 days
after the last administration of study medication. Incidence rates for
adverse events will be coded by preferred term and system organ class,
as per the most up-to-date version of the Medical Dictionary for
Regulatory Activities. Adverse events will be summarized according
to intensity (mild, moderate, severe) and causality by investigator's
assessment; adverse events of special interest include bronchospasm
and haemoptysis, amongst others mentioned previously.
3. Discussion
The RESPIRE trials are designed to evaluate whether intermittent,
long-term therapy with Ciprofloxacin DPI is superior to placebo in
prolonging the time to exacerbation and/or reducing the frequency of
exacerbations over 48 weeks in patients with NCFB. Other studies of
inhaled antibiotics in this patient population have had limited success
in this respect, perhaps in part due to multiple aetiologies included and
the heterogeneous nature of NCFB [5]. With the largest NCFB patient
population ever studied in interventional trials, the RESPIRE pro-
gramme has the potential to provide important insight into long-term
treatment outcomes in patients with NCFB who have been treated with
Ciprofloxacin DPI.
The RESPIRE trials have strict entry criteria in terms of NCFB
disease: the patient population is limited to patients with one of two
major aetiologies (post-infectious or idiopathic) and who experience
frequent exacerbations (at least two documented in the previous
12 months). In particular, patients with a primary diagnosis of COPD
are excluded, as these patients may have a different disease course and
a variable response to therapy [30]. It is intended that the patient
phenotype required by the RESPIRE trials will represent the two major
aetiological groups reported in most case series. The strict entry criteria
may also help to define the patient population who could be likely
benefit the most from treatment with a long-term inhaled antibiotic
therapy.
Stratification for chronic macrolide therapy will provide efficacy
and safety data that are specific for patients who are being treated with
long-term macrolides and those who are not. Data from a US cohort
indicate that 14% of NCFB patients receive chronic macrolide therapy
[31] and evidence for their use as long-term anti-inflammatory treat-
ment is growing [32]. It is therefore, important to explore the use of
investigational NCFB therapies in patients on long-term macrolide
therapy.
The RESPIRE trials are unique in their inclusion of patients with
seven different Gram-positive and Gram-negative pathogens. The
majority of NCFB patients are chronically colonized (~72%); com-
monly with P. aeruginosa and H. influenzae [11]. While P. aeruginosa is
associated with a worse clinical course in NCFB compared with other
bacteria [7,14,33–35] pathogens such as Moraxella catarrhalis and
Staphylococcus aureus often colonize NCFB patients and may also be
associated with poorer outcomes [11]. In addition, bacterial load has
been correlated to number of exacerbations [36] and it is therefore
important to determine the impact of inhaled antibiotic therapy on
bacterial burden in the lungs of bronchiectasis patients. Ciprofloxacin
DPI showed efficacy at reducing bacterial burden in a phase II study
and a trend towards fewer exacerbations [29]; these data seem to
suggest that the microbiological efficacy of Ciprofloxacin DPI has an
impact on its clinical efficacy. By including seven different pathogens,
the RESPIRE studies could provide insight into this aspect of treatment
as well as help to ensure that the trial cohort is representative of the
overall population of NCFB patients with frequent exacerbations
[36–38]. Stratification by positive baseline P. aeruginosa culture will
also allow exploration of whether all patients benefit from Ciproflox-
acin DPI or if benefits are dependent on the presence or absence of this
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pathogen.
The impact of Ciprofloxacin DPI on bacterial resistance is an equally
important consideration as inhaled antibiotics are likely to have
different impacts on microbial elimination and resistance compared
to systemic antibiotics, owing to the high local concentrations and low
systemic exposure [39]. The duration of the RESPIRE trials (approxi-
mately 1-year) should provide an adequate duration for an exploration
of efficacy, safety and microbial susceptibility data relevant to long-
term therapy.
Another key, unique feature of the RESPIRE programme is the
investigation of both a 14-day and 28-day on/off treatment regimen.
On/off dosing was originally chosen for inhaled tobramycin in CF to
maximize benefits while reducing the emergence of resistance [40] and
indeed, early studies of aerosolized tobramycin in patients with CF,
demonstrated improvements in spirometry assessments of lung function
peaked at 4 weeks [41–42]. However, the CF-based rationale for a 28-
day cycle may not apply in NCFB, and indeed there is no evidence for
the appropriate cycle duration in these patients. In phase II studies of
Ciprofloxacin DPI in CF and NCFB patients, peak reductions in bacterial
load were observed between days 8–15 [29,43]. These data imply that a
14 days treatment regimen may be beneficial to maximize the anti-
microbial effect while minimizing the recovery time for surviving
bacterial colonization in this patient population. The testing of two
different intermittent regimens in the RESPIRE trials should therefore
allow evaluation of NCFB-specific dosing strategies and may enhance
understanding of the effect of antibiotic cycles on treatment outcomes.
The lack of a validated and well accepted definition of exacerbation
is an important issue in the management NCFB. Identifying and
documenting exacerbations in this patient population is challenging
and the varying definitions used by individual centres and trials can
make the comparison of research and results difficult. By using a
stringent definition of exacerbation in the RESPIRE trials the impact of
variability between clinical assessments should be reduced.
Furthermore, the application of a more stringent, but possibly less
sensitive, definition will likely reduce the number of protocol-defined
exacerbations observed during the trial, but will hopefully also limit
these events to bacterial exacerbations that could potentially be
reduced by antibiotic therapy. Secondary endpoints, using a compara-
tively less stringent definition of exacerbation will serve as confirma-
tory analyses. Additional, descriptive assessments involving other
definitions of exacerbation should allow further insight into the most
clinically relevant criteria for defining exacerbations in patients with
NCFB.
It is intended that the unique aspects of the RESPIRE programme
described above will lead to advances in the understanding and
treatment of NCFB, including optimal treatment regimen, and provide
an important new therapy to improve the lives of NCFB patients who
experience frequent exacerbations and have evidence of respiratory
pathogens including but not limited to, P. aeruginosa.
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